Drug intelligence / Profile preview

peanut extract

Development stage: Phase 2
Lead developer: Sanofi
Administration: Sublingual

Overview

Peanut extract is a pharmaceutical preparation derived from peanuts, utilized in sublingual immunotherapy (SLIT) for the treatment of peanut allergy. It is administered sublingually to induce desensitization and reduce hypersensitivity reactions in peanut allergic individuals through controlled exposure to peanut allergens. In the provided context, it is a key component of SAR439794, a sublingual immunotherapy product being developed by Sanofi, which is adjuvanted with Glucopyranosyl Lipid A (GLA).

Other names: peanut allergen-Johns Hopkins University-peanut allergy

Beyond the preview

Go deeper on peanut extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on peanut extract.

Explore the full profile